1. A multicenter, randomized controlled comparison of three renutrition strategies for the management of moderate acute malnutrition among children aged from 6 to 24 months (the MALINEA project).
- Author
-
Vray M, Hedible BG, Adam P, Tondeur L, Manirazika A, Randremanana R, Mainassara H, Briend A, Artaud C, von Platen C, Altmann M, and Jambou R
- Subjects
- Acute Disease, Africa, Age Factors, Albendazole administration & dosage, Anti-Bacterial Agents adverse effects, Antiparasitic Agents administration & dosage, Azithromycin adverse effects, Child Development, Child, Preschool, Female, Humans, Infant, Infant Nutrition Disorders diagnosis, Infant Nutrition Disorders microbiology, Infant Nutrition Disorders physiopathology, Male, Malnutrition diagnosis, Malnutrition microbiology, Malnutrition physiopathology, Multicenter Studies as Topic, Prebiotics adverse effects, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Azithromycin administration & dosage, Flour adverse effects, Food, Fortified adverse effects, Gastrointestinal Microbiome drug effects, Infant Nutrition Disorders therapy, Infant Nutritional Physiological Phenomena, Malnutrition therapy, Nutritional Status, Prebiotics administration & dosage
- Abstract
Background: The aim of this open-label, randomized controlled trial conducted in four African countries (Madagascar, Niger, Central African Republic, and Senegal) is to compare three strategies of renutrition for moderate acute malnutrition (MAM) in children based on modulation of the gut microbiota with enriched flours alone, enriched flours with prebiotics or enriched flours coupled with antibiotic treatment., Methods: To be included, children aged between 6 months and 2 years are preselected based on mid-upper-arm circumference (MUAC) and are included based on a weight-for-height Z-score (WHZ) between - 3 and - 2 standard deviations (SD). As per current protocols, children receive renutrition treatment for 12 weeks and are assessed weekly to determine improvement. The primary endpoint is recovery, defined by a WHZ ≥ - 1.5 SD after 12 weeks of treatment. Data collected include clinical and socioeconomic characteristics, side effects, compliance and tolerance to interventions. Metagenomic analysis of gut microbiota is conducted at inclusion, 3 months, and 6 months. The cognitive development of children is evaluated in Senegal using only the Developmental Milestones Checklist II (DMC II) questionnaire at inclusion and at 3, 6, and 9 months. The data will be correlated with renutrition efficacy and metagenomic data., Discussion: This study will provide new insights for the treatment of MAM, as well as original data on the modulation of gut microbiota during the renutrition process to support (or not) the microbiota hypothesis of malnutrition., Trial Registration: ClinicalTrials.gov, ID: NCT03474276 Last update 28 May 2018.
- Published
- 2018
- Full Text
- View/download PDF